Nordic Life Science 1
WuXi AppTec ADVERTORIAL From discovery to deliver
y: INSIDE WUXI APPTEC’S GLOBAL CRDMO MODEL EVERY DRUG can be made and every disease can be treated. That’s the vision of WuXi AppTec, the contract research, development and manufacturing organization (CRDMO) that helps accelerate timelines to bring breakthrough treatments to the patients who need them most. I N T E R V I E W W I T H DAVE MADGE, PH . D. , V P DISCOV ERY SERV I CES , WUXI A PP T EC A “One of our major contributions is early investment into technology platforms which are then made available to all our clients, to facilitate and accelerate their programs.” S A GLOBAL CRDMO, WuXi AppTec offers endto-end pharmaceutical services across Europe, Asia, and North America. In 2024 alone, it has helped thousands of customers in over 30 countries transform scientific discoveries into breakthrough therapies. Its integrated platform provides solutions for every stage of drug development, from early discovery and preclinical testing to clinical development and commercial manufacturing, with the goal of getting effective treatments to patients faster. The company is dedicated to building its platform in Europe in order to support clients locally, anchored by two European sites – one in Germany and one in Switzerland – to facilitate that. Across Scandinavia, WuXi AppTec is well established and currently serves around 60 companies in pre-clinical drug discovery. Dave Madge, Vice President of Discovery Services, keeps a close eye on the Northern European region, where he feels that a lot of impressive things are happening in life sciences. “It’s a dynamic landscape with increasing numbers of early-stage companies, since there are more venture capital firms that are building a footprint in Scandinavia, and we also see expansion in the number of incubators in Denmark and Sweden. These bring new opportunities and strategies to translate early-stage ideas from academia towards therapies. That’s a direction that we’re very well plugged into,” Dave Madge explains. “The dedication in Scandinavia to accelerate the translation of early-stage ideas into patient therapies has been well PHOTO CRELUX, A WUXI APPTEC COMPANY